Detalles de la búsqueda
1.
Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis.
Headache
; 63(6): 730-742, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37313616
2.
Reducing the physical, social, and emotional impact of episodic migraine: Results from erenumab STRIVE and ARISE phase III randomized trials.
Headache
; 62(2): 159-168, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35137394
3.
Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis.
Headache
; 62(5): 624-633, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35593783
4.
A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention.
Cephalalgia
; 41(1): 33-44, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33231489
5.
Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies.
Cephalalgia
; 41(14): 1458-1466, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34407654
6.
Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension.
Cephalalgia
; 41(1): 6-16, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33269951
7.
Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study.
Cephalalgia
; 41(13): 1285-1297, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34171973
8.
Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial.
Eur J Neurol
; 28(5): 1716-1725, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33400330
9.
Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.
Headache
; 61(6): 927-935, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34153117
10.
Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine.
Headache
; 61(4): 653-661, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33764538
11.
Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial.
J Headache Pain
; 22(1): 110, 2021 Sep 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34537006
12.
Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials.
J Headache Pain
; 22(1): 81, 2021 Jul 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-34301173
13.
A Controlled Trial of Erenumab for Episodic Migraine.
N Engl J Med
; 377(22): 2123-2132, 2017 11 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-29171821
14.
Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study.
Cephalalgia
; 40(6): 543-553, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32216456
15.
The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response.
Cephalalgia
; 40(1): 28-38, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31816249
16.
The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response.
Headache
; 60(9): 2026-2040, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32851644
17.
Efficacy and safety of erenumab in women with a history of menstrual migraine.
J Headache Pain
; 21(1): 95, 2020 Aug 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32746775
18.
Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.
Cephalalgia
; 39(7): 817-826, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30982348
19.
Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions.
Cephalalgia
; 39(14): 1798-1808, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-31707815
20.
Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine.
Cephalalgia
; 39(11): 1455-1464, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31146544